Capricor's Cell Therapy Trial Shows Promising Results for Muscular Dystrophy
Capricor's clinical trial
Learning from the success of earlier research findings, the company Capricor therapeutics started the clinical trial of CAP-1002 in August 2015. They used the percutaneous intervention to deliver these stem cells to the heart through a catheter, and this collection of preliminary results was completed in November 2017.
The research aimed to find out the safety and effectiveness of cell-based therapy in patients with muscular dystrophy, with heart function being the primary focus. Apart from heart function, they also measured any improvement in the strength of limbs and quality of life in general.
